IASLC-TTLC 2024 - The IASLC 2024 Targeted Therapies of Lung Cancer Meeting
Feb 21 - Feb 24, 2024 | Santa MonicaCAUS
LARVOL is not affiliated with The IASLC 2024 Targeted Therapies of Lung Cancer Meeting and all trademarks, logos, and brand names are property of their respective owners
Condition
Product
MOA
Trial Name/ID
Showing 2 abstracts linked to Trials
Observational Cohort Study of Osimertinib Plus Capmatinib for Patients with EGFR-Mutant (mt +) NSCLC with Progression on Osimertinib Monotherapy and Development of MET Amplification or Overexpression
Osimertinib, Platinum, Etoposide As Initial Treatment for Patients with Metastatic EGFR Mutant Lung Cancers with Concurrent TP53 and RB1 Alterations